Cargando…

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells

Mutants, KCP‐4 and PC‐5, resistant to an anticancer agent, cisplatin, were selected in multiple steps from human epidermoid KB carcinoma cells and human prostate PC‐3 carcinoma cells, respectively. KCP‐4 and PC‐5 were 63 and 10 fold more resistant to cisplatin than the parental cells, respectively....

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Ryu‐ichi, Mutoh, Masato, Niwa, Kiyoshi, Yamada, Kazutaka, Aikou, Takashi, Nakagawa, Masayuki, Kuwano, Michihiko, Akiyama, Shin‐ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1994
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919474/ https://www.ncbi.nlm.nih.gov/pubmed/8200854 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02376.x

Ejemplares similares

Vincristine‐resistant Human Cancer KB Cell Line and Increased Expression of Multidrug‐resistance Gene
por: Kohno, Kimitoshi, et al.
Publicado: (1988)

Altered Expression of Epidermal Growth Factor Receptor Gene in a Classical Multidrug‐resistant Variant of a Human Cancer Cell Line, KB
por: Takano, Hiroshi, et al.
Publicado: (1989)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

Expression of Thymidine Phosphorylase in Human Gastric Carcinoma
por: Takebayashi, Yuji, et al.
Publicado: (1996)

Carcinoma Matrix Controls Resistance to Cisplatin through Talin Regulation of NF-kB
por: Eberle, Karen E., et al.
Publicado: (2011)

Multidrug Resistance Reversal Activity of Taxoids from Taxus cuspidate in KB‐C2 and 2780AD Cells
por: Kobayashi, Jun'ichi, et al.
Publicado: (2000)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

Culture media, DMSO and efflux affect the antibacterial activity of cisplatin and oxaliplatin
por: Gupta, A., et al.
Publicado: (2022)

Multi-drug-resistance efflux in cisplatin-naive and cisplatin-exposed A2780 ovarian cancer cells responds differently to cell culture dimensionality
por: Koshkin, Vasilij, et al.
Publicado: (2021)

Coronary vasospasm induced by cisplatin for seminoma
por: Sasaki, Wataru, et al.
Publicado: (2019)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection
por: Kidera, Yasuhiro, et al.
Publicado: (2014)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes.
por: Shen, D. W., et al.
Publicado: (1995)

Differences in Substrate Specificity among Glutathione Conjugates (GS‐X) Pump Family Members: Comparison between Multidrug Resistance‐associated Protein and a Novel Transporter Expressed on a Cisplatin‐resistant Cell Line (KCP‐4)
por: Ueda, Kaoru, et al.
Publicado: (1999)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Potentiation of Some Anticancer Agents by Dipyridamole against Drug‐sensitive and Drug‐resistant Cancer Cell Lines
por: Asoh, Kuni‐ichi, et al.
Publicado: (1989)

Systemic cisplatin increases the number of patients showing positive off-frequency masking audiometry
por: Hiraumi, Harukazu, et al.
Publicado: (2023)

Altered Expression of γ‐Glutamylcysteine Synthetase, Metallothionein and Topoisomerase I or II during Acquisition of Drug Resistance to Cisplatin in Human Ovarian Cancer Cells
por: Kikuchi, Yoshihiro, et al.
Publicado: (1997)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Cisplatin-Induced Eosinophilic Pneumonia
por: Ideguchi, Hideharu, et al.
Publicado: (2014)

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
por: Terada, Yoshio, et al.
Publicado: (2013)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Mitochondrial Involvement in Cisplatin Resistance
por: Cocetta, Veronica, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
por: Saitoh, Jun-ichi, et al.
Publicado: (2017)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin
por: Gong, Xin, et al.
Publicado: (2017)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence
por: Iram, Sana, et al.
Publicado: (2019)

Inhibition of Cisplatin‐mediated DNA Damage in vitro by Ribonucleotides
por: Seki, Shuji, et al.
Publicado: (1993)

Calcium efflux from the endoplasmic reticulum regulates cisplatin-induced apoptosis in human cervical cancer HeLa cells
por: SHEN, LUYAN, et al.
Publicado: (2016)

The Relationship Between Actin Cytoskeleton and Membrane Transporters in Cisplatin Resistance of Cancer Cells
por: Shimizu, Takahiro, et al.
Publicado: (2020)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Thioridazine Enhances Cisplatin-Induced DNA Damage in Cisplatin-Resistant Human Lung Cancer Cells
por: Luo, Yuanyuan, et al.
Publicado: (2022)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rm5q4um5uhh2kb7t0r7pi8g0mm